Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Lawrie, Theresa A ^a   Rabbie, Roy ^b   Thoma, Clemens ^c   Morrison, Jo ^d  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ALOPECIA; ANEMIA; CANCER STAGING; CYTOREDUCTIVE SURGERY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; DRUG ADMINISTRATION; NEOPLASM; OVARY TUMOR; ANALOGS AND DERIVATIVES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898978943     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010482.pub2     Document Type: Review

References (51)

1. Bookman MA. Erratum. Journal of Clinical Oncology 2009;27(13):2305.
2. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002.
3. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology 2006;24(Suppl 18):A-5002:256s.
4. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology 2009;27(9):1419-25.
5. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. International Journal of Gynecological Cancer 2003;13(6):735-40.
6. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecologic Oncology 2003;90:(2 Part 2):S1-7.
7. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al.Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. Journal of Clinical Oncology 2011;29(27):3628-35.
8. Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, et al.Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BioMedCentral (BMC) Cancer 2006;6:202. http://www.biomedcentral.com/1471-2407/6/202.
9. Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, et al.Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology 2009;76(1):49-54.
10. Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Vernaglia Lombardi A, et al.Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO-2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532).
11. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Ferrandina G, et al.Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508).
12. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Legge F, et al.Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033).
13. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Legge F, et al.Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO-2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010.
14. Pignata S, Scambia G, Savarese A, Zagonel V, Gebbia V, Scollo P, et al.Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO-2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014).
15. Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, et al.Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Oncology 2005;69(4):348-53.
16. Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, et al.Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecologic Oncology 2009;114(2):206-9.
17. A'Hern R, Gore ME. The impact of doxorubicin on survival in advanced ovarian cancer. Journal of Clinical Oncology 1995;13:726-32.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85(5):365-76.
19. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al.for the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine 2011;365:2473-83.
20. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al.Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Journal of Clinical Oncology 2010;28(20):3323-9.
21. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989;299(6712):1363-7.
22. CTCAE. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
23. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining for heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Healthcare: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
25. European Medicines Agency. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000089/WC500020173.pdf 2010 (accessed 24 January 2013).
26. European Medicines Agency. Avastin (bevacizumab) product page. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf.
27. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. European Journal of Cancer 2009;45(6):931-91.
28. FIGO CinGO. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics 2009;105(1):3-4.
29. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 1997;54(Suppl 4):15-21.
30. Gabizon AA. Stealth liposomes and tumour targeting: one step further in the quest for the magic bullet. Clinical Cancer Research 2001;7:223-5.
31. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Lyon, France.
32. Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou G, Bamias A, Fountzilas G, et al.A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine 2010;8:3.
33. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring Inconsistency in meta-analysis. BMJ 2003;327:557-60.
34. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
35. Jacobs I, Bridges J, Reynolds C, Stabile I, Kemsley P, Grudzinskas J, et al.Multimodal approach to screening for ovarian cancer. The Lancet 1988;331(8580):268-71.
36. Janssen-Cilag P, Ltd. CAELYX Product Information. http://www.janssen.com.au/Products/Caelyx. Amended 4 January 2011 (accessed 24 January 2013).
37. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. The Lancet 2009;374(9698):1331-8.
38. Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD006910.pub2]
39. Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, et al.Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecologic Oncology 2010;116(3):323-5.
40. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al.Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The Lancet Oncology 2009;10(4):327-40.
41. National Institute for Health and Clinical Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55). London: National Institute for Health and Clinical Excellence, 2003.
42. National Institute for Health and Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer (CG122). London: National Institute for Health and Clinical Excellence 2011.
43. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. Journal of Clinical Oncology 1991;9:1668-74.
44. Ozols RF, Wilson JK, Weltz MD, Grotzinger KR, Myers CE, Young RC. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Research 1980;40:4109-12.
45. Perren TJ, Swart AM, Pfisterer J, Ledemann JA, Pujade-Lauraine E, Kristensen G, and the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011;365:2484-96.
46. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
47. Kosary CL. Chapter 16: Cancer of the ovary. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J editor(s). Cancer Survival Among Adults: US SEER Program, 1988-2001. Bethesda: US Department of Health and Human Services; National Cancer Institute, 2007:133-44.
48. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, et al.Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology 2013;14(3):236-43.
49. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92(3):205-16.
50. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety 2001;24:903-20.
51. Zunino F, Pratesi G. Antitumour antibodies. Oxford Textbook of Oncology. 2nd Edition. Oxford, UK: Oxford University Press, 2002:715-27.